Education
About Us
Working with TipRanks
Follow Us
Hemostemix Inc (TSE:HEM)
:HEM
HEM Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.43
Previous CloseN/A
Volume356.00K
Average Volume (3M)239.81K
Market Cap
C$19.84M
Enterprise ValueC$5.05M
Total Cash (Recent Filing)C$705.70K
Total Debt (Recent Filing)C$4.94M
Price to Earnings (P/E)―
Beta0.13
Next Earnings
Sep 01, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding146,947,170
10 Day Avg. Volume66,697
30 Day Avg. Volume239,809
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-0.74
Price to Sales (P/S)0.00
P/FCF Ratio-0.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Hemostemix News
PremiumCompany Announcements
Hemostemix Secures $336,500 in Private Placement to Bolster Growth
PremiumCompany Announcements
Hemostemix Raises $2.67M to Boost Stem Cell Research
PremiumCompany Announcements
Hemostemix Secures $1.8M in Private Placement
PremiumCompany Announcements
Hemostemix Launches $4M Financing for Stem Cell Therapy Growth
PremiumCompany Announcements
Hemostemix Partners with CytoImmune, Boosts ACP-01 Production
PremiumCompany Announcements
Hemostemix Accelerates Cell Therapy Production with CytoImmuneOptions Prices
Currently, No data available
---
Ownership Overview
11.91% Insiders
―
Mutual Funds
― Other Institutional Investors
88.09% Public Companies and
Individual Investors
HEM FAQ
What was Hemostemix Inc’s price range in the past 12 months?
Hemostemix Inc lowest stock price was C$0.04 and its highest was C$0.42 in the past 12 months.
What is Hemostemix Inc’s market cap?
Hemostemix Inc’s market cap is C$19.84M.
When is Hemostemix Inc’s upcoming earnings report date?
Hemostemix Inc’s upcoming earnings report date is Sep 01, 2025 which is in 64 days.
How were Hemostemix Inc’s earnings last quarter?
Currently, no data Available
Is Hemostemix Inc overvalued?
According to Wall Street analysts Hemostemix Inc’s price is currently Overvalued.
Does Hemostemix Inc pay dividends?
Hemostemix Inc does not currently pay dividends.
What is Hemostemix Inc’s EPS estimate?
Hemostemix Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Hemostemix Inc have?
Hemostemix Inc has 146,947,170 shares outstanding.
What happened to Hemostemix Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Hemostemix Inc?
Currently, no hedge funds are holding shares in TSE:HEM
Hemostemix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
170.00%
12-Months-Change
Fundamentals
Return on Equity
34.47%
Trailing 12-Months
Asset Growth
1201.79%
Trailing 12-Months
Company Description
Hemostemix Inc
Hemostemix Inc., a biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of critical limb ischemia in Canada and the United States, as well as for the treatment of heart and peripheral arterial diseases. The company is also developing various types of cell products, such as synergetic cell populations and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.
Technical Analysis
Kane Biotech
―
Resverlogix
―
Sirona Biochem
―
BetterLife Pharma
―
PharmaTher Holdings Ltd
―